.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,674,790

« Back to Dashboard

Details for Patent: 7,674,790

Title:Processes of making and using pharmaceutical formulations of antineoplastic agents
Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.
Inventor(s): Ugwu; Sydney (Wheeling, IL), Radhakrishnan; Vinay (Laurence Harbor, NJ), Ihnat; Peter M. (Brooklyn, NY), Witchey-Lakshmanan; Leonore C. (Piscataway, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Filing Date:Jan 13, 2006
Application Number:11/332,721
Claims:1. A process of making a pharmaceutical formulation comprising the steps of: (i) dissolving at least one dissolution enhancing agent in at least one aqueous diluent wherein said dissolution enhancing agent is selected from the group consisting of L-histidine, L-threonine, L-asparagine, L-serine, and L-glutamine; and (ii) adding Temozolomide or a pharmaceutically acceptable salt thereof.

2. The process according to claim 1, wherein step (i) further comprises adding: a) a polysorbate; b) at least one bulking agent; c) at least one buffer; and d) at least one pH adjuster.

3. The process according to claim 1, or 2 further comprising lyophilizing the formulation to form a lyophilized powder.

4. The lyophilized powder, produced by the process of claim 3.

5. An article of manufacture comprising a container containing the lyophilized powder of claim 4.

6. The article of manufacture according to claim 5, wherein said container is a syringe or vial.

7. The article of manufacture according to claim 5, further comprising a volume of at least one aqueous diluent suitable for reconstitution of said lyophilized powder.

8. The process according to claim 1 or 2, wherein the dissolution enhancing agent is L-threonine.

9. The process according to claim 2, further comprising filtering said solution.

10. The process according to claim 2, wherein the bulking agent is mannitol.

11. The process according to claim 2, wherein the buffer is sodium citrate dihydrate.

12. The process according to claim 2, wherein the pH adjuster is hydrochloric acid.

13. The process according to claim 2, wherein the polysorbate is polysorbate 80.

14. The process according to claim 2, wherein: the dissolution enhancing agent is L-threonine, the bulking agent is mannitol, the buffer is sodium citrate dihydrate, the pH adjuster is hydrochloric acid, and the polysorbate is polysorbate 80.

15. The process according to claim 8, wherein Temozolomide is present in an amount ranging from about 4 wt % to about 16 wt %, and L-threonine is present in an amount ranging from about 8 wt % to about 20 wt %.

16. The process according to claim 14, wherein Temozolomide is present in an amount ranging from about 4 wt % to about 16 wt %, L-threonine is present in an amount ranging from about 8 wt % to about 20 wt %, mannitol is present in an amount ranging from about 40 wt % to about 56 wt %, sodium citrate dihidrate is present in amount ranging from about 15 wt % to about 28 wt %, hydrochloric acid is present in an amount ranging from about 4 wt % to about 8 wt %, and polysorbate 80 is present in an amount ranging from about 4 wt % to about 16 wt %.

17. The process according to claim 14, wherein Temozolomide is present in about 8 wt %, L-threonine is present in an about 13 wt %, mannitol is present in about 48 wt %, sodium citrate dihidrate is present in about 19 wt %, hydrochloric acid is present in about 5 wt %, and polysorbate 80 is present in about 9 wt %.

18. The process according to claim 17, further comprising lyophilizing the formulation to form a lyophilized powder.

19. The process according to claim 14, further comprising lyophilizing the formulation to form a lyophilized powder.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc